ATLANTA New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients ( Abstract #0546 )
/PRNewswire/ According to Coherent Market Insights, the Global Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 20,671.1.
SEATTLE, Sept. 6, 2022 /PRNewswire/ According to Coherent Market Insights, the Global Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 20,671.1 million
/PRNewswire/ According to Coherent Market Insights, the Global Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 20,671.1.